| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00703-4014-18 | 00703-4014 | Leuprolide Acetate | Leuprolide Acetate | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 6, 2000 | Mar 31, 2011 | No Longer Used | ||
| 00310-0951-30 | 00310-0951 | Goserelin acetate | Zoladex | 10.8 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 5, 2003 | Mar 31, 2020 | No Longer Used | |
| 00185-7400-85 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 4, 1998 | In Use | ||
| 50090-2027-00 | 50090-2027 | Goserelin acetate | Zoladex | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Sep 23, 2015 | In Use | ||
| 62935-0223-05 | 62935-0223 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 26, 2002 | In Use | |||
| 70121-2537-06 | 70121-2537 | Leuprolide acetate | Leuprolide acetate | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 7, 2022 | In Use | |||
| 83634-0454-61 | 83634-0454 | Leuprolide acetate | Leuprolide Acetate | 5.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 15, 2025 | In Use | ||
| 72851-0042-01 | 72851-0042 | Leuprolide | CAMCEVI | 42.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Dec 30, 2022 | In Use | ||
| 47335-0936-40 | 47335-0936 | Leuprolide Acetate | Leuprolide Acetate | Hormonal Therapy | GnRH Agonist | Dec 15, 2014 | In Use | ||||
| 52544-0092-76 | 52544-0092 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Mar 11, 2010 | Oct 31, 2018 | No Longer Used | |||
| 00121-2106-02 | 00121-2106 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/1ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb 1, 2025 | In Use | ||
| 72664-0611-28 | 72664-0611 | Leuprolide Acetate | Leuprolide Acetate | Hormonal Therapy | GnRH Agonist | Oct 25, 2020 | In Use | ||||
| 00185-7400-14 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 6, 2011 | In Use | ||
| 00023-5902-04 | 00023-5902 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 15, 2000 | In Use | ||||
| 62935-0461-50 | 62935-0461 | Leuprolide acetate | Eligard | 45.0 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 6, 2023 | In Use | ||
| 52544-0188-76 | 52544-0188 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 29, 2001 | Oct 31, 2018 | No Longer Used | |||
| 85043-0045-04 | 85043-0045 | Leuprolide acetate | Vabrinty | 45.0 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 4, 2025 | In Use | ||
| 00069-0298-60 | 00069-0298 | Glasdegib | Daurismo | 25.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec 10, 2018 | In Use | |
| 50242-0140-86 | 50242-0140 | Vismodegib | Erivedge | 150.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Apr 9, 2013 | In Use | |
| 00078-0645-15 | 00078-0645 | Sonidegib | Odomzo | 200.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Jul 24, 2015 | Dec 31, 2017 | No Longer Used |
| 00069-1531-30 | 00069-1531 | Glasdegib | Daurismo | 100.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec 10, 2018 | In Use | |
| 50242-0140-01 | 50242-0140 | Vismodegib | Erivedge | 150.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Jan 30, 2012 | In Use | |
| 72694-0728-40 | 72694-0728 | Vorasidenib | VORANIGO | 40.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
| 72694-0879-10 | 72694-0879 | Vorasidenib | VORANIGO | 10.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
| 45802-0368-53 | 45802-0368 | Imiquimod | Imiquimod | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Jul 12, 2012 | In Use |
Found 11765 results — Export these results
Home